ORKA — Oruka Therapeutics Share News
0.000.00%
Last trade - 00:00Oruka's experimental drug helps clear psoriasis in mid-stage study (updated)
Oruka Therapeutics' psoriasis drug meets main goal of mid-stage study
Brief: Oruka Therapeutics May Offer Up To $1 Billion Of Securities From Time To Time - SEC Filing
U.S. RESEARCH ROUNDUP-Cencora, Kennametal, Regeneron Pharmaceuticals
U.S. RESEARCH ROUNDUP-Abbvie, BristolMyers Squibb, Diversified Healthcare
Brief: Oruka Therapeutics Files For Mixed Shelf Of Upto $500 Million - SEC Filing
U.S. STOCKS ON THE MOVE-Regeneron, Elf Beauty, Eli Lilly
U.S. STOCKS ON THE MOVE-Oruka Therapeutics, Regeneron, natgas companies
Oruka Therapeutics jumps after positive early-stage study data for psoriasis drug
Brief: Oruka Therapeutics Announces Positive Interim Phase 1 Results For Orka-001
Oruka Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Oruka Therapeutics Announces Ind Clearance For Everlast-A Phase 2A Trial Of Orka-001 In Psoriasis With Phase 1 Data To Be Presented At Eadv In September
Brief: Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer
Oruka Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview
Oruka Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE- Teladoc Health, Veritex, New York Community Bancorp
U.S. STOCKS ON THE MOVE- AppLovin, Regal Rexnord, Talkspace
Leerink Partners starts drug developer Oruka with 'outperform'
U.S. RESEARCH ROUNDUP- Constellation Energy, Eli Lilly, Talen Energy